Atrinsic Inc. (NASDAQ:PTIX – Get Free Report) rose 1.2% during mid-day trading on Wednesday . The company traded as high as $0.41 and last traded at $0.41. 2,326 shares changed hands during trading, a decline of 93% from the average daily volume of 34,219 shares. The stock had previously closed at $0.4050.
Atrinsic Stock Performance
The company’s 50 day moving average price is $0.61 and its 200 day moving average price is $0.71. The company has a market cap of $742,100.00, a price-to-earnings ratio of -0.05 and a beta of 1.01.
Atrinsic Company Profile
Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc is headquartered in New York, New York.
Featured Articles
- Five stocks we like better than Atrinsic
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
- Why Palantir’s Google Cloud Deal Could Change the Debate
Receive News & Ratings for Atrinsic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrinsic and related companies with MarketBeat.com's FREE daily email newsletter.
